8-K filing — BioCardia, Inc. (BCDA)
Filed: 2026-09-23 AccNo: 0001437749-26-031011 Size: 172 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
BioCardia Advancing Towards Shonin Pre-Market Regulatory Submission To Japan's Pharmaceutical And Medical Device Agency In Q4; Plans To File Follow-On De Novo Pre-Submission For Helix Transendocardial Delivery Catheter System
BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term milestones.BioCardia is working
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioCardia Shares Fall 10% After Hours: Here's Why
BioCardia shares fall 10% after hours after Nasdaq confirms the company regained listing compliance.
BioCardia Says FDA Finalized Pre-Submission Meeting Minutes For Helix Transendocardial Delivery Catheter; Plans Follow-On Pre-Submission This Quarter Toward Potential De Novo Approval